- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04299165
Smartphone-App as Maintenance Program in COPD (AMOPUR)
Impact of a Smartphone Application (KAIA COPD-App) in Combination With Activity Monitoring as Maintenance Program Following Pulmonary Rehabilitation in COPD: an International Multi-centered Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, controlled, open-label, multi-centered trial carried out at in-patient PR-hospital centers in Germany and Switzerland . The interventions will involve use of KAIA COPD-app program (Arm 1) or an active comparator i.e. usual care (Arm 2). Patients completing an in-hospital PR-Program and consenting to participate in the study will be screened for the inclusion and exclusion criteria and enrolled in the study. After fulfillment of the screening requirements, they will be randomized into one of the two arms with parallel group assignment in a 1:1 ratio. The training program will be delivered to the participants grouped to the arm 1 through KAIA COPD-App and arm 2 as provided in regular recommendations or standard of care through the PI. In total, 104 participants will be included to the trial. Treatment period will last for 24 weeks. Electronic versions of Questionnaires will be used to collect patient reported assessments remotely. The primary outcome measure is the change in physical activity of the intervention group in comparison to the control group, measured over one week as mean steps per day with the Polar A 370 activity tracker, from baseline (end of PR) to 6-months follow-up. The secondary outcome measures are functional exercise capacity, health status, sleep quality, exacerbation rate, depression and anxiety symptoms assessed at several intervals.
This study seeks to prove the implications of the Kaia COPD mobile application in COPD patients after PR. The app offers educational, exercise training plus activity monitoring and motivational program that can be easily implemented in the patient's home-setting enabling patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Schönau am Königssee, Germany
- Koczulla
-
-
-
-
-
Wald, Switzerland, 8636
- Zürcher RehaZentren Wald
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- COPD Patients willing and able to sign informed consent for use of their pseudonymized clinical data within the scope of the present interventional trial
- COPD patients who have completed an in-hospital pulmonary rehabilitation program with an average duration of 2-3 weeks.
- Diagnosis of COPD, defined as forced expiratory volume in 1s/forced vital capacity (FEV1/FVC) <70% predicted, FEV1<80 % predicted after bronchodilation, with or without chronic symptoms (cough, sputum production) corresponding to a GOLD stage II-IV
- Completion of the screening period and fulfilling of the randomization criteria as defined by the protocol
- Ability to use a smartphone and smartphone-apps
- Willingness to wear an activity tracker during study period of 6 months
- Patients ≥40 years of age.
- Knowledge of German language to understand study material, assessments and contents of the COPD-App
Exclusion Criteria:
- The Patient is not able to conduct the exercise training program due to physical, cognitive or safety reasons, as judged by investigator; e.g., lower limb joint surgery within preceding 3 months, unstable cardiac disease, predominant neurological limitations, planned surgical or other interventions disturbing the study intervention.
- Significant psychiatric disorders, legal incapacity or limited legal capacity.
- Patients participation in another clinical trial with an investigational medication within 30 days prior to study entry.
- Patients already using the KAIA COPD App
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Device: KAIA COPD-App (Medical Mobile Application).
The study intervention is an exercise training program that requires only a chair or water bottles, consisting of training elements with progressive levels of intensity, individually adaptable to the participant's exercise level.
This training program is delivered to the participants with the help of KAIA COPD-App.
Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
|
The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
|
Active Comparator: Usual Care
The Training of the control-group is performed by regular recommendations/ Standard of care.
Standard of care in this context means to hand out the brochure " Besser Leben mit COPD " including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
|
The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steps per day as mean over one week from baseline until the treatment end
Time Frame: Every day for 6 months
|
The primary outcome are the steps per day as mean over one week from baseline (second week after discharge from PR) to 6 months follow-up in the intervention group in comparison to the control group as an equivalent for the physical activity of the participants, measured by an activity tracker (Polar A370-Watch).
|
Every day for 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dyspnea
Time Frame: Baseline, Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
Dyspnea will be assessed by the COPD Assessment Test (CAT) which measures the impact of COPD on a person's health status (8 questions, 6-point Likert-type scale)
|
Baseline, Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
Functional exercise capacity using I min Sit to stand test
Time Frame: Baseline (day 0), Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
Functional exercise capacity will be assessed by the widely-used and validated 1-min sit-to-stand test (STS).
The patients are guided through an integrated video with a stop watch in an ePRO to perform the test in a right way in home settings.
|
Baseline (day 0), Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
Quality of life through SAS-CRQ
Time Frame: Baseline (day 0), Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
SAS- CRQ The chronic respiratory questionnaire, a self-administered instrument, includes 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items).
Patients will be scored for the Quality of life around their experience on a 7-point scale ranging from 1 (maximum impairment) to 7 (no impairment).
|
Baseline (day 0), Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
Subjective health status
Time Frame: At the Baseline (Day 0) and every 4 weeks (V2 to V8) until the end of treatment period of 24 weeks
|
A feeling thermometer scale allows respondents to rank how positively individuals feels about the quality of life to measure individuals' subjective health status.
The scale ranges from a minimum of 0 to a maximum of 100.
|
At the Baseline (Day 0) and every 4 weeks (V2 to V8) until the end of treatment period of 24 weeks
|
Sleep efficacy and total sleep time
Time Frame: Every night for 6 months of treatment period
|
Sleep efficacy (SE) and total sleep time (TST)will be measured by the Polar A370 Watch every night during the treatment period.
|
Every night for 6 months of treatment period
|
Motivation for reaching his or her individual defined goal of physical activity
Time Frame: At the Baseline (Day 0) and every 4 weeks (V2 to V8) until the end of treatment period of 24 weeks
|
This assessment is linked to the intervention group using COPD App only.
During monthly visits, a certain number of steps will be fixed as a goal for the patients in the COPD application.
|
At the Baseline (Day 0) and every 4 weeks (V2 to V8) until the end of treatment period of 24 weeks
|
Assessment of usability
Time Frame: End of the treatment period of 24 weeks from baseline
|
This assessment is linked to the intervention group using COPD App only.
The use of the application will be assessed every week through patient data reports captured in the COPD Application.
|
End of the treatment period of 24 weeks from baseline
|
Rate, number and severity of adverse events
Time Frame: At baseline (day 0) and every 2 weeks after, until the end of the treatment period of 24 weeks
|
The AEs and SAEs will be documented to assess the safety related to the use of the application and trainings, in the home settings.
|
At baseline (day 0) and every 2 weeks after, until the end of the treatment period of 24 weeks
|
Rate, number and severity of device deficiencies
Time Frame: At baseline(day 0) and every 2 weeks after, until the end of the treatment period of 24 weeks
|
The DDs will be documented to assess the performance of the device and usability.
|
At baseline(day 0) and every 2 weeks after, until the end of the treatment period of 24 weeks
|
Hospital Anxiety and Depression Scale
Time Frame: Baseline (day 0), Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
The HADS Questionnaire will be used to measure anxiety and depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
|
Baseline (day 0), Visit 5 (12 weeks) and Visit 8( 24 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc Spielmanns, MD, Reha Zentrum Wald, Zürich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kaia COPD 001
- DRKS00017275 (Registry Identifier: DRKS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Kaia COPD Application
-
Kaia Health SoftwareCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Kaia Health SoftwareWashington University School of MedicineCompleted
-
China-Japan Friendship HospitalNot yet recruitingChronic Obstructive Pulmonary Disease
-
Kaia Health SoftwareBrigham and Women's HospitalUnknownLow Back PainUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic Obstructive
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCOPD (Chronic Obstructive Pulmonary Disease)United States
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Gelb, Arthur F., M.D.RecruitingEmphysema | COPD, Emphysema, Asthma COPD OverlapUnited States
-
AstraZenecaRecruiting
-
Karolinska InstitutetDalarna County Council, SwedenCompleted